Literatur
-
1
Besinger U A, Toyka K V, Homberg M. et al .
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.
Neurology.
1983;
33
1316-1321
-
2 Hohlfeld R, Melms A, Schneider C. et al .Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener H-C, Kennard C (eds) Neurological disorders - course and treatment. Amsterdam; Elsevier 2003: p 1341-1362
-
3
Toyka K V.
Ptosis in myasthenia gravis: Extended fatigue and recovery bedside test.
Neurology.
2006;
67
1524
-
4
Toyka K V, Drachman D B, Pestronk A. et al .
Myasthenia gravis: passive transfer from man to mouse.
Science.
1975;
190
397-399
-
5
Toyka K V, Drachman D B, Griffin D E. et al .
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
N Engl J Med.
1977;
296
125-131
-
6 Hohlfeld R, Toyka K V. Therapies. In: Oosterhuis HJGH, de Baets M (eds) Myasthenia gravis. CRC Press, Inc 1993: 235-261
-
7
Marx A, Wilisch A, Schultz A. et al .
Pathogenesis of myasthenia gravis.
Virchows Arch Int J Pathol.
1997;
430
355-364
-
8
Leite M I, Strobel P, Jones M. et al .
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.
Ann Neurol.
2005;
57
444-448
-
9
Lindstrom J.
An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.
Clin Immunol Immunopathol.
1977;
7
36-43
-
10
Toyka K V, Heininger K.
[Acetylcholinrezeptor Antikörper bei der Diagnostik der Myasthenia gravis. Untersuchung von 406 Fällen].
Dtsch Med Wochenschr.
1986;
111
1435-1439
-
11
Pflughaupt K W, Becker T, Toyka K V.
Azetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis: stichprobenartige Erhebung zur Zuverlässigkeit des Doppelimmun-Präzipitationstests.
Akt Neurol.
1994;
21
63-65
-
12
Buchwald B, Ahangari R, Weishaupt A. et al .
Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: Their neutralization by intravenous immunoglobulins.
Muscle & Nerve.
2005;
31
487-494
-
13
Hoch W, McConville J, Helms S. et al .
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Nat Med.
2001;
7
365-368
-
14
Vincent A, Bowen J, Newsom-Davis J. et al .
Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets.
Lancet Neurol.
2003;
2
99-106
-
15
Farrugia M E, Robson M D, Clover L. et al .
MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Brain.
2006;
129
1481-1492
-
16
Heininger K, Hartung H-P, Toyka K V. et al .
Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels.
Ann N Y Acad Sci.
1987;
505
898-900
-
17
Gajdos P, Chevret S, Clair B. et al .
Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.
Ann Neurol.
1997;
41
789-796
-
18
Gajdos P, Tranchant C, Clair B. et al .
Treatment of Myasthenia Gravis exacerbation with intravenous immunoglobulin - A randomized double-blind clinical trial.
Arch Neurol.
2005;
62
1689-1693
-
19
Flachenecker P, Taleghani B M, Gold R. et al .
Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.
Transfus Sci.
1998;
19, Suppl
43-46
-
20 Gold R, Toyka K V. Immuntherapie neurologischer Erkrankungen. Bremen; 2006
-
21
Schneider-Gold C, Hartung H P, Gold R.
Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases.
Muscle & Nerve.
2006;
34
284-291
-
22
Drachman D B, Jones R J, Brodsky R A.
Treatment of refractory myasthenia: „Rebooting” with high-dose cyclophosphamide.
Ann Neurol.
2003;
53
29-34
-
23
Chan A, Lee D H, Linker R. et al .
Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.
J Neurol.
2007;
254
1604-1606
-
24
Strobel P, Bauer A, Puppe B. et al .
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.
J Clin Oncol.
2004;
22
1501-1509
-
25
Hohlfeld R, Toyka K V, Besinger U A. et al .
Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.
Ann Neurol.
1985;
17
238-242
-
26
Burns T M, Russell J A, LaChance D H. et al .
Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome.
Ann Neurol.
2003;
53
270-273
-
27
Bain P G, Motomura M, Newsom-Davis J. et al .
Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Neurology.
1996;
47
678-683
-
28
Buchwald B, Weishaupt A, Toyka K V. et al .
Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals.
Eur J Neurosci.
1998;
10
281-290
-
29
Buchwald B, Ahangari R, Weishaupt A. et al .
Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome.
Ann Neurol.
2002;
51
673-680
Prof. Ralf Gold
Neurologische Klinik der Ruhr-Universität Bochum
St. Josef-Hospital
Gudrunstraße 56
44791 Bochum
Email: ralf.gold@rub.de
